Callan Capital LLC Raises Holdings in Becton, Dickinson and Company (NYSE:BDX)

Callan Capital LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 7,100 shares of the medical instruments supplier’s stock after acquiring an additional 61 shares during the quarter. Callan Capital LLC’s holdings in Becton, Dickinson and Company were worth $1,659,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth $27,000. OLD Point Trust & Financial Services N A bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $29,000. Scarborough Advisors LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth about $32,000. Rise Advisors LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth about $38,000. Finally, ICA Group Wealth Management LLC purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $42,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BDX shares. Citigroup lowered their price target on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target for the company. Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Evercore ISI decreased their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Trading Up 1.3 %

NYSE BDX opened at $234.63 on Friday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $67.81 billion, a price-to-earnings ratio of 51.68, a PEG ratio of 1.91 and a beta of 0.42. The stock’s 50-day simple moving average is $235.42 and its two-hundred day simple moving average is $235.54. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same period in the prior year, the business posted $2.96 earnings per share. The company’s revenue was up 2.3% on a year-over-year basis. Research analysts forecast that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio is 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.